Abstract: The present invention discloses metal (III) complex of a biuret-amide based macrocyclic ligand as green catalysts that exhibit both excellent reactivity for the activation of H2O2 and high stability at low pH and high ionic strength. The invention also provides macrocyclic biuret amide based ligand for designing of functional peroxidase mimics. Further, the present invention discloses synthesis of said metal (III) complex of a biuret-amide based macrocyclic ligand.

Abstract: The present invention provides implantable medical devices coated with polyelectrolyte assemblies that are fabricated by layer-by-layer deposition of nucleic acid and polycation. Such devices facilitate the local delivery of a nucleic acid contained in the polyelectrolyte assembly into a cell or tissue at an implantation site. Also provided are methods of fabricating and using implantable medical devices according to the invention.

Abstract: A spermatogonial stem cell line that is derived from testes of rats characterized by a desirable genetic background can serve as a source for cells to transplant into male-sterile recipient animals that are immuno-compatible with the spermatogonial line. Rat cells thus transplanted readily develop into fertilization-competent, haploid male gametes, with little or no endogenous sperm competition generated by the testes of the male-sterile recipient. This approach, constituting the first vector system for the use of rat spermatogonial lines from in vitro culture in generating mutant rats on a desired genetic background, effects maximal germline transmission of donor haplotypes from the transplanted spermatogonial cells.

Abstract: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.

Abstract: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.

Abstract: The present invention relates to a biomarker for the identification of exposure to lower aliphatic saturated aldehydes by using micro RNA and a method for the identification of exposure to lower aliphatic saturated aldehydes using the same. In this invention, the micro RNA at least 1.5 fold up-regulated by exposure to lower aliphatic saturated aldehydes and the micro RNA up to 0.66 fold down-regulated by the same were selected. These two micro RNAs can be effectively used as the biomarker for the monitoring of lower aliphatic saturated aldehydes and for the risk assessment thereby and at the same time as a tool to investigate the mechanism of toxicity caused by such lower aliphatic saturated aldehydes.

Abstract: The embodiments of the present invention are directed to discrete, cis-acting regulatory elements that include a barrier element, an insulating element, a silencing element, and matrix attachment regions (“MARs”). Additional embodiments of the present invention are directed to nucleic acid molecules that are useful for facilitating stable transgene expression within a chromatin environment. Additional embodiments of the present invention are directed to recombinant expression vectors including nucleic acid molecules of the present invention that can be incorporated into artificial chromosomes, eukaryotic cell-lines, non-human transgenic animals, and transgenic plants, to improve recombinant protein production in a broad range of eukaryotic hosts, and pharmaceutical compositions including nucleic acid molecules of the present invention that are also useful for gene therapy in the treatment of various genetic diseases.

Abstract: The disclosure provides methods, devices, compositions and kits for diagnosing or predicting transplant status or outcome in a subject who has received a transplant. The methods comprise determining the presence or absence of one or more nucleic acids from a donor transplant, wherein said one or more nucleic acids from said donor are identified based on a predetermined marker profile, and diagnosing or predicting transplant status or outcome based on the presence or absence of said one or more nucleic acids.

Abstract: Provided is a modified bacteriophage capable of infecting a target bacterium, which bacteriophage includes an ?/? small acid-soluble spore protein (SASP) gene encoding a SASP which is toxic to the target bacterium, wherein the SASP gene is under the control of a constitutive promoter which is foreign to the bacteriophage and the SASP gene.

Abstract: The present invention relates to a method for producing a L-arabinose utilizing yeast strain for the production of ethanol, whereby a yeast strain is modified by introducing and expressing araA gene (L-arabinose isomerase), araB gene (L-ribulokinase D121-N) and araD gene (L-ribulose-5-P 4-epimerase) and carrying additional mutations in its genome or overexpressing a TAL1 (transaldolase) gene, enabling it to consume L-arabinose, to use it as the only carbon source, and to produce ethanol, as well as a method for producing ethanol using such a modified strain.

Abstract: The present invention provides novel stem cells, nucleotide sequences and proteins therefrom. More specifically, the present invention provides Pax7+/Myf5? stem cells and methods for identifying and isolating them. Also provided is a MEGF10 nucleotide sequence and protein.

Abstract: The present invention relates to permanent cell lines from chiropterans suitable for amplification and production of microbial agents, preferably viruses, and its use for diagnostic or therapeutic purposes.

Abstract: The present invention relates to a method of identifying a compound involved in pain, the use of Epsti1 nucleic acid or Epsti1 protein for identifying a compound involved in pain as well as methods of diagnosing algesia involving the same.

Abstract: A method for producing D-lactic acid in high yield, and to provide a method for producing D-lactic acid with high selectivity, in which optical purity is high and a by-product organic acid is small. In one aspect, a microorganism, wherein activity of pyruvate formate-lyase (pfl) is inactivated or decreased, and further activity of Escherichia coli-derived NADH-dependent D-lactate dehydrogenase (ldhA) is enhanced, is cultured to efficiently produce D-lactic acid. With regard to a method for enhancing ldhA activity, by linking, on a genome, a gene encoding ldhA with a promoter of a gene which controls expression of a protein involved in a glycolytic pathway, a nucleic acid biosynthesis pathway or an amino acid biosynthesis pathway, suitable results are obtained compared to the method for enhancing expression of the gene using an expression vector.

Abstract: This invention provides methods and compositions for incorporation of an unnatural amino acid into a peptide using an orthogonal aminoacyl tRNA synthetase/tRNA pair. In particular, an orthogonal pair is provided to incorporate 5-hydroxy-L-tryptophan in a position encoded by an opal mutation.

Abstract: Compositions and methods relating to immunostimulatory RNA oligomers are provided. The immunostimulatory RNA molecules are believed to represent natural ligands of one or more Toll-like receptors, including Toll-like receptor 7 (TLR7) and Toll-like receptor 8 (TLR8). The compositions and methods are useful for stimulating immune activation. Methods useful for screening candidate immunostimulatory compounds are also provided.

Abstract: Described are methods for detection of neuronal pathologies using quantitative analysis in bodily fluids of synapse and/or neurite small RNAs and application of these methods to early diagnosis and monitoring of neurodegenerative diseases and other neurological disorders.

Abstract: Gram-negative bacteria, and compositions containing the bacteria, resistant to one or more stress conditions, including, but not limited to, CO2, acid pH, and high osmolarity, having reduced TNF-?induction having a mutation in one or more lipid biosynthesis genes, e.g., msbB, rendered stress-resistant by a mutation in the zwf gene are provided. Methods for prophylaxis or treatment of a virally induced disease in a subject comprising administering preferably attenuated stress-resistant gram-negative bacterial mutants. and for prophylaxis or treatment of a virally induced disease in a subject comprising administering one or more stress-resistant gram-negative bacterial mutants as vectors for the delivery of one or more therapeutic molecules are provided.

Abstract: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.

Abstract: Patterned SAM arrays and methods of preparing patterned SAM arrays are disclosed. Advantageously, the methods used to prepare the patterned SAM arrays allow for controlling SAM spot-to-spot conditions such as ligand identity and ligand density, which allows for preparing a wide range of SAM spots in a single array format. Additionally, the patterned SAM arrays of the present disclosure support the culture of a range of cell types. The patterned SAM arrays offer the ability to rapidly screen substrate components for influencing cell attachment, spreading, proliferation, migration, and differentiation.